TuisOGN • NYSE
add
Organon & Co
Vorige sluiting
$11,04
Dagwisseling
$10,89 - $11,21
Jaarwisseling
$10,89 - $23,10
Markkapitalisasie
2,82 mjd USD
Gemiddelde volume
4,19 m
P/V-verhouding
3,28
Dividend-opbrengs
10,23%
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,59 mjd | -0,38% |
Bedryfskoste | 598,00 m | 14,78% |
Netto inkomste | 109,00 m | -80,04% |
Netto winsgrens | 6,85 | -79,95% |
Wins per aandeel | 0,90 | 2,27% |
EBITDA | 375,00 m | -17,40% |
Effektiewe belastingkoers | 15,50% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 675,00 m | -2,60% |
Totale bates | 13,10 mjd | 8,65% |
Totale aanspreeklikheid | 12,63 mjd | 4,13% |
Totale ekwiteit | 472,00 m | — |
Uitstaande aandele | 257,95 m | — |
Prys om te bespreek | 6,03 | — |
Opbrengs op bates | 5,76% | — |
Opbrengs op kapitaal | 7,95% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 109,00 m | -80,04% |
Kontant van bedrywe | 390,00 m | -1,76% |
Kontant van beleggings | -296,00 m | -265,43% |
Kontant van finansiering | -82,00 m | -6,49% |
Netto kontantverandering | -88,00 m | -131,54% |
Beskikbare kontantvloei | 268,75 m | -27,88% |
Meer oor
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Wikipedia
Gestig
1923
Webwerf
Werknemers
10 000
